Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV

Bowman C1, Ambrose A1, Simoes P1, Florman K1, Kanitkar T1, Katiyar A1, Hunter A1, Hart J1, Barber TJ12
1 - Ian Charleson Day Centre, Royal Free London NHS Foundation Trust, NW3 2QG.
2 - Institute for Global Health, UCL

Introduction

Use of DTG-2DR has been shown to maintain virological suppression in HIV affected people. [1-3] In our centre, regimens include DTG/3TC, DTG/RPV, DTG/FTC. Multiple tablet regimens (MTR) were issued until single tablet regimens (STR) were available. Since 2015 we prescribed DTG-2DR for 620 people out of a total cohort of 3133 (19.8%).

Methods

Clinic database search 01/01/15-31/10/21 conducted for all people receiving DTG-2DR. Microsoft Excel™ spreadsheet used to compile data. Demographic, tolerability and HIV related data were analysed.

Results

Demographics

620 people were prescribed DTG-2DR. Of these, 561 had complete data for analysis. Majority of the patients were male (n=446, 79.5%), female n = 115, 20.5%). The median age was 54 (IQR 46-59). The most common risk factors for HIV infection were MSM sex (n=343, 61.1%), heterosexual sex (n=177 31.5%) and injecting drug use (n=10, 1.2%). Median time to DTG-2DR prescription from diagnosis was 16 years. Median time on treatment was 11 and 28 months for DTG-XTc and DTG-RPV respectively.

Efficacy

537/561 (97.2%) people had an undetectable viral load (VL) at time of first prescription. 3 had missing pre-prescription VL. 21 had VL>50 copies/ml prior to initiation. Median VL was 2585 copies/ml (IQR 132, 5370). 9 people (1.6%) initiated DTG-3TC naively, and all suppressed after initiation (2 DTG/3TC MTR, 7 DTG/3TC STR. MTR would later be switched to STR). The remaining 552 switched to or continued DTG-2DR. The great majority remained suppressed at data censor (n= 546, 99.0%, chart 1). The most common regimen was DTG/3TC as STR (n=398, 72.1%, see table below).

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Number of Patients</th>
<th>Percentage of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTG/3TC</td>
<td>460</td>
<td>83.3%</td>
</tr>
<tr>
<td>MTR</td>
<td>62</td>
<td>11.2%</td>
</tr>
<tr>
<td>STR</td>
<td>398</td>
<td>72.1%</td>
</tr>
<tr>
<td>DTG/FTC</td>
<td>18</td>
<td>3.3%</td>
</tr>
</tbody>
</table>

Tolerability and Adverse Events

4 patients died (0.1%) but cause of death was not related to HIV or ART. Majority of people tolerated DTG-2DR with no issue. 70 people (12.7%) switched off DTG-2DR (57 DTG/XTC 13 DTG/RPV). 59 switched for tolerability (10.7%) and 11 (2%) for blipping or failure. Most common side-effects were neurological (n=13, 18.6%), psychiatric (n=12 (17.1%), or weight gain (n=10, 14.3%).

Resistance

5 failures were investigated with resistance tests, mutations were identified in one person. He received TDF/3TC/DTG, alongside multiple cardiovascular medicines, and switched to DTG/3TC MTR due to TDF related side-effects. He suppressed initially but months later his VL was undetectable [100 copies/ml]. Genotyping revealed reverse transcriptase (M184V, K103N) and integrase (T66A, G118R, E138K) mutations. He switched to TAF/FTC/DRV/c STR and resuppressed.

Discussion

TANGO, SALSA and SWORD studies have shown non-inferiority of DTG-2DR to standard triple regimens in maintaining virological suppression. [1-3] Our data, a large cohort of 561 mostly MSM, supports these findings with 98.0% suppressed at data censor. Side-effects noted were similar to those encountered in the literature. It is interesting to note that the majority of viral blips occurred on MTR regimens. There were a low number of failures, and proportionally these were more likely to occur on MTR. One episode of resistance occurred in a person receiving DTG-3TC MTR, a finding similar to GEMINI study, where failure with resistance only occurred on MTR. [4]

Conclusion

Majority of DTG/3TC use is in stable switch. A minority of patients switch due to tolerability. Low number of virologic failures noted, though one developed INI resistance; VF associated with MTR and it is imperative switch to STR occurs when available, commensurate with trial data showing no failure with resistance if DTG/3TC STR used. Overall DTG-2DR demonstrates high efficacy in a real-world setting.

References